MARKET

MLYS

MLYS

Mineralys Therapeutics, Inc.
NASDAQ
25.86
-0.73
-2.75%
After Hours: 25.86 0 0.00% 19:30 09/25 EDT
OPEN
26.55
PREV CLOSE
26.59
HIGH
26.70
LOW
25.21
VOLUME
1.19M
TURNOVER
--
52 WEEK HIGH
47.65
52 WEEK LOW
22.30
MARKET CAP
2.29B
P/E (TTM)
-6.0986
1D
5D
1M
3M
1Y
5Y
1D
Mineralys Therapeutics (MLYS) In Focus As Lorundrostat Data Nears Fair Value Debate
Simply Wall St · 1d ago
How Investors Are Reacting To Mineralys Therapeutics (MLYS) Long Term Blood Pressure Data
Simply Wall St · 2d ago
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Barchart · 2d ago
Mineralys Therapeutics To Present New Long-Term Efficacy And Safety Data From Ongoing Transform-HTN Open-Label Extension Trial Of Aldosterone Synthase Inhibitor Lorundrostat At AHA Scientific Sessions 2026
Benzinga · 3d ago
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
Barchart · 3d ago
Weekly Report: what happened at MLYS last week (0914-0918)?
Weekly Report · 6d ago
Weekly Report: what happened at MLYS last week (0907-0911)?
Weekly Report · 09/14 09:32
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 09/09 15:05
More
About MLYS
Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA.

Webull offers Mineralys Therapeutics Inc stock information, including NASDAQ: MLYS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MLYS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MLYS stock methods without spending real money on the virtual paper trading platform.